We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our programs are designed to provide relevant information to support people with bleeding disorders and their families with their ability to make informed choices.
Take a look.
Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved. Find something to do.
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
News & Events
According to a recent study, most post pubertal girls and adolescents who experience heavy menstrual bleeding are not screened for von Willebrand disease (VWD), despite years of recommendations from the American College of Obstetricians and Gynecologists. Investigators came to this conclusion after conducting a retrospective analysis of a national claims database of public and privately insured individuals from 2011-2013.
Most postpubertal girls and adolescents who experience heavy menstrual bleeding are not screened for von Willebrand disease (VWD), despite years of recommendations from the American College of Obstetricians and Gynecologists.
A group of Canadian researchers recently published findings from a clinical study on the use of prophylaxis with a standard half-life recombinant factor VIII (SHL-rFVIII) therapy to treat boys with severe hemophilia A. They investigated an approach to prophylactic therapy in which patients began by receiving weekly infusions of SHL-rFVIII and ultimately transition to “tailored frequency-escalated prophylaxis.” The lead investigator of the study was Professor Brian M Feldman, MD of the Division of Rheumatology at The Hospital for Sick Children in Toronto.
Researchers investigated an approach to prophylactic therapy in which patients began by receiving weekly infusions of standard half-life recombinant factor VIII and ultimately transition to “tailored frequency-escalated prophylaxis."
NHF's Red Tie Soiree paid tribute to longtime advocates for the bleeding disorders community while looking forward to the future of research and treatment.